Department of Respiratory Medicine Ministry of Education Key Laboratory of Child Development and Disorders Chongqing Key Laboratory of Pediatrics Children's Hospital of Chongqing Medical University National Clinical Research Center for Child Health and Disorders Chongqing China
Auto-generated profile, based on publicly available information
Yuanyuan Zhang
Department of Respiratory Medicine Ministry of Education Key Laboratory of Child Development and Disorders Chongqing Key Laboratory of Pediatrics Children's Hospital of Chongqing Medical University National Clinical Research Center for Child Health and Disorders Chongqing China
Asthma, chronic pulmonary obstructive disease (COPD), cystic fibrosis, and acute respiratory infections are severe respiratory conditions that significantly contribute to global morbidity and mortality. Airway mucus hypersecretion is an important common pathophysiological and clinical manifestation of these diseases and is closely associated with adverse clinical outcomes. At present, the management of airway mucus hypersecretion lacks a viable clinical intervention. However, the revelation that the EGFR signaling pathway acts as a convergent intracellular pathway for many inflammatory mediators indicates that it exhibits the greatest potential for inhibiting excessive mucus production. This review provides a comprehensive overview of the role of EGFR in airway mucus hypersecretion and the therapeutic progress of targeting it, intending to improve clinicians' understanding of the mechanism and offer insights and recommendations for developing novel pharmaceutical interventions to regulate mucus secretion.